Rubicon Research IPO Overview
The Rubicon Research Ltd IPO is a combination of a fresh issue and an Offer for Sale (OFS). Key details include:
-
Issue Size: ₹1,377.50 crore (Fresh Issue ₹500 crore + OFS ₹877.50 crore)
-
Price Band: ₹461 – ₹485 per share (Rubicon Research IPO price)
-
Lot Size: 30 shares (~₹14,550 per lot)
-
IPO Date: October 9–13, 2025 (Rubicon Research IPO date)
-
Allotment Date: October 14, 2025
-
Listing Date: October 16, 2025 (tentative)
Investors can apply for the Rubicon Research Ltd IPO through their brokerage accounts during the subscription period.
Financial Snapshot
The company has shown strong financial performance:
-
Revenue (FY25): ₹1,296.22 crore
-
Profit After Tax (PAT): ₹134.36 crore
-
EBITDA: ₹267.89 crore
-
Return on Net Worth: 29%
-
PAT Margin: 10.37%
These numbers make the Rubicon Research IPO an attractive option for investors looking at growth and profitability metrics in the pharmaceutical sector.
Global Presence & Business Strength
Rubicon Research has subsidiaries in the US, Canada, Singapore, and Australia, along with manufacturing and R&D facilities in India and Canada. Certifications like USFDA, WHO-GMP, and Health Canada approvals enhance credibility.
A strong R&D focus and global footprint are key strengths for the Rubicon Research Ltd IPO, making it appealing to investors eyeing long-term growth.
Rubicon Research IPO GMP Trends
The Rubicon Research IPO GMP reflects market sentiment before listing. GMP, or Grey Market Premium, indicates the potential listing price above the IPO band. Investors often track Rubicon Research IPO GMP to gauge demand and market interest.
As of the latest trends, the IPO has seen strong subscription, especially among institutional investors, signaling robust market confidence.
Key Risks
While promising, the Rubicon Research IPO comes with risks:
-
US Market Dependency: Around 98% of revenue is from the US.
-
Customer Concentration: 71% of revenue comes from the top five clients.
-
Regulatory Compliance: Operating in multiple regions with stringent norms.
Investors should assess these risks along with potential returns before subscribing to the Rubicon Research Ltd IPO.
Conclusion
The Rubicon Research IPO presents a notable opportunity in the pharmaceutical sector. By considering the Rubicon Research IPO price, IPO date, and GMP trends, investors can make informed decisions. This IPO is suitable for those seeking exposure to a growing company with a strong global presence, solid financials, and a focused R&D strategy.
Read more details about the IPO here: Rubicon Research IPO
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any investment decisions.
